EN DE
Watch Medi-Caps Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medi-Caps Limited (523144) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Medi-Caps Limited stock ₹25.14, price ₹22.45, upside +12.0%, quality 46 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Health Care IN

MC Medi-Caps Limited logo Thin data Nov 16, 2026

Medi-Caps Limited

523144 · BSE

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value ₹25.14 · Fairly valued 
Quality 46/100 
Revenue last quarter 21% below a year ago. 
Falling price (downtrend) 
Weak Growth (revenue 5y −26.4 %/yr in INR) 
Loss-making · -10.4% net margin (TTM) 
Negative free cash flow 
Trails peers (4/12) 
Narrow moat 9/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Medi-Caps Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹86.35 ₹20.83 Fair Value ₹25.14 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ₹20.83 – ₹86.35 · fair‑value band ₹18.85 – ₹31.42 · the ₹22.45 price screens below the ₹25.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Medi-Caps in your weekly email

Every Wednesday you see whether Medi-Caps is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medi-Caps Limited manufactures and sells empty hard gelatin capsule shells in India. It offers halal gelatin, liquid fill, sodium lauryl sulfate free, and preservative free capsules. The company was incorporated in 1983 and is based in Indore, India.

Stock analysis

Medi-Caps Limited (523144) currently trades at ₹22.45, while our estimate is ₹25.14, so the stock looks roughly fairly valued today (gap 10.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹18.85 (bear) to ₹31.42 (bull), the price of ₹22.45 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Health Care sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Medi-Caps Limited reported revenue of ₹124M in FY2026 versus ₹699M in FY2022, a compound −35.1%/yr. Reported net income was −₹30.4M in FY2026.

Key figures

Market cap ₹280M (≈ $3.0M) Micro · P/S ratio 0.66 · EPS (TTM) ₹1.10 · Net margin −24.5% · Return on assets (EBIT) −1.0% (5-year average) · Operating margin −9.7% · Revenue growth (YoY) −20.9% · Free cash flow −₹78.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Health Care peers we cover trades at −38% fair-value upside, at 12%, 523144 screens cheaper than that median.

Fair Value

Bear ₹18.85 Fair Value ₹25.14 Bull ₹31.42
Price ₹22.45 · Upside +12.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 11
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−51.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.4%
Start year 2021 (pandemic). Over 10 years: −11.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.3% (2021) → −90.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch 523144, get fair value alerts →

Compare Medi-Caps Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 58 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside +12.0% · Above median
Profitability
Return on assets −2.6% · Bottom 25%
Net margin (12 months) −10.4% · Bottom 25%
Operating margin (12 months) −9.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −20.9% · Bottom 25%
Dividend yield (12 months) 0.0% · Bottom 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 0.25× · Cheapest 25%
P/S (12 months) 0.66× · Cheapest 25%
EV/EBITDA 17.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)49 · sector 12
FUTURE (revenue growth)0 · sector 68
PAST (return on equity)0 · sector 24
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,430 KRW 47,019 KRW +142% vs 523144
DongKook Pharmaceutical Co 086450 23,050 KRW 28,372 KRW +23% vs 523144
ST Pharm Co 237690 71,200 KRW 61,182 KRW −14% vs 523144
Vivozon Pharmaceutical Co 082800 3,000 KRW 2,179 KRW −27% vs 523144
Oscotec Inc 039200 34,250 KRW 21,262 KRW −38% vs 523144
NatureCell Co 007390 21,950 KRW 11,176 KRW −49% vs 523144
Mezzion Pharma Co 140410 64,500 KRW 31,450 KRW −51% vs 523144
BINEX Co 053030 6,680 KRW 1,844 KRW −72% vs 523144
Caregen Co 214370 27,900 KRW 5,414 KRW −81% vs 523144
SHUKRAPHAR SHUKRAPHAR ₹82.24 ₹9.14 −89% vs 523144

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medi-Caps Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medi-Caps Limited Fair Value". https://www.fairvalue-calculator.com/stock/523144

Frequently asked questions

Is Medi-Caps Limited (523144) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ₹25.14 versus a price of ₹22.45, about +12% upside (fairly valued).
What is the fair value of 523144?
Our estimate for Medi-Caps Limited is ₹25.14 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₹22.45.
What is the quality score of 523144?
Medi-Caps Limited has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medi-Caps Limited (523144)?
Our calculated price target is the estimate of ₹25.14 (as of Nov 16, 2026). Cautious scenario ₹18.85, optimistic scenario ₹31.42. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medi-Caps Limited stock forecast for 2026?
Our estimate puts fair value at ₹25.14, about +12% upside versus a price of ₹22.45 (fairly valued). Cautious scenario ₹18.85, optimistic scenario ₹31.42. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Medi-Caps Limited (523144)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medi-Caps Limited it is ₹25.14 per share (as of Nov 16, 2026), against a price of ₹22.45.
Is Medi-Caps Limited stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 523144 trades below its calculated fair value: price ₹22.45, fair value ₹25.14, a gap of about +12% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 523144?
No. The price is what the market pays today (₹22.45); the fair value is what the company's own numbers justify (₹25.14). For Medi-Caps Limited the two are ₹2.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medi-Caps Limited worth?
The market values Medi-Caps Limited at about ₹280M (market capitalisation, as of Nov 16, 2026). Per share that is ₹22.45; our models calculate a fair value of ₹25.14 per share.
What do the bullish and bearish scenarios say about 523144?
Our models span a range for Medi-Caps Limited: cautious scenario ₹18.85, base ₹25.14, optimistic ₹31.42 per share (as of Nov 16, 2026, price ₹22.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 523144 from its 52-week high?
Medi-Caps Limited trades at ₹22.45, about 39% below its 52-week high of ₹36.95 and 8% above the low of ₹20.83 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹25.14 is for.
Which stocks are comparable to Medi-Caps Limited?
From the same area (Health Care) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medi-Caps Limited stock attractive at the current price?
The data as of Nov 16, 2026: price ₹22.45, calculated fair value ₹25.14 (+12%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Medi-Caps Limited currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medi-Caps Limited (523144)?
The closing price on Nov 16, 2026 was ₹22.45. Our estimate is ₹25.14, about +12% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medi-Caps Limited right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Medi-Caps Limited

How large is the market capitalisation of Medi-Caps Limited (523144)?
The market capitalisation of Medi-Caps Limited is ₹280M (≈ $3.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medi-Caps Limited (523144)?
The price-to-sales ratio of Medi-Caps Limited is 0.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medi-Caps Limited (523144)?
Earnings per share at Medi-Caps Limited are ₹1.10. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medi-Caps Limited (523144)?
The net margin of Medi-Caps Limited is −24.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Medi-Caps Limited (523144)?
On an EBIT basis the return on assets of Medi-Caps Limited is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medi-Caps Limited (523144)?
The operating margin of Medi-Caps Limited is −9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medi-Caps Limited (523144)?
Revenue at Medi-Caps Limited is down 20.9% versus a year earlier (3y avg −36.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medi-Caps Limited (523144) generate?
The free cash flow of Medi-Caps Limited is −₹78.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medi-Caps Limited (523144) carry?
The net debt of Medi-Caps Limited is ₹619K (fiscal year 2020). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medi-Caps Limited in the live analysis

One click puts Medi-Caps Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.